Haemonetics Corporation Stock News

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-pois

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.

Opsens Inc shares surged 47% to $2.84 in midday trading on Tuesday after the cardiology-focused medical device company agreed to be acquired by global healthcare firm Haemonetics Corporation for C$

Here is how Haemonetics (HAE) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is how Haemonetics (HAE) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.

Haemonetics (HAE) announces the first treatment of patients in Germany with the VASCADE MVP Venous Vascular Closure system.

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Stryker (SYK). But which of these two stocks presents investors with the better value o

GM, KB, CRBG, AXS and HAE have been added to the Zacks Rank #1 (Strong Buy) List on August 10, 2023.

The robust volume growth and price benefits in the Plasma business drive Haemonetics' (HAE) fiscal first-quarter performance.

While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare

Haemonetics (HAE) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.58 per share a year ago.